VIENNA : Nobody will get preferential access to a potential COVID-19 drug developed by vaccine maker Themis Bioscience, which is being bought by US pharmaceuticals firm Merck & Co Inc, the Austrian firm's chief executive said on Thursday. "Merck has already demonstrated in the past ...
that it makes vaccines available to anybody who needs them," Erich Tauber told Reuters on Thursday, adding a potential vaccine would be made available globally. "It is one of the reasons why we have decided to cooperate with Merck." Merck, which has largely kept to the sidelines of the race for COVID-19 treatments, said on Tuesday it was buying Themis Bioscience, which is developing its vaccine in collaboration with the Institut Pasteur in Paris.